A £48 Million Vaccine Harm Assessment: Unraveling the Costs and Controversies
The NHS has been scrutinized for spending nearly £50 million on an outsourced firm, Crawford & Company Adjusters, to assess claims of medical harm caused by vaccines. This figure is an astonishing eight times the initial estimate and surpasses the total compensation awarded to those affected by Covid vaccines. The contract, initially valued at £6 million, has over a year remaining, but a new company will soon take over the assessment work.
The surge in costs can be attributed to the volume of claims exceeding expectations. Over 22,000 claims related to Covid vaccines have been filed, with most involving the AstraZeneca jab. However, only a minuscule 1% have resulted in compensation payouts, handled by the Vaccine Damage Payment Scheme (VDPS).
Critics argue that the contract's nature is peculiar, given the significant uncertainty at the time of its creation. A law professor suggests that a shorter contract with a claim processing cap would have been more appropriate. The NHS, in response to the spiraling costs, attributes the prolonged procurement process to the complexity of the contract and the variability of public sector organization timelines.
As the controversy unfolds, the public is left questioning the efficiency and transparency of the NHS's decision-making process. The case of Crawford & Company Adjusters highlights the challenges in managing large-scale medical assessments and the potential implications for taxpayer funds.
